ADTRAN
Adtran today announced that Netnod is leveraging its optical pumping cesium atomic clock technology to bring precise, reliable and assured timing to Sweden’s critical national infrastructure. Protecting the country’s timing services is vital for the nation’s economy, encompassing finance, digital services and next-generation telecoms networks, such as 5G. By upgrading its timing network with the coreSync™ OSA 3300-HP, Netnod, the leading provider of internet exchange, DNS and time services in the Nordics, is enhancing the accuracy, stability and longevity of synchronization services across the region. The solution meets the need for precise timing, supporting the smooth operation and evolution of digital applications and services. It represents a significant advancement in timing that enhances Sweden’s position in digital innovation and cybersecurity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311684053/en/
Netnod is using Adtran’s synchronization technology for ultra-precise and reliable timing across Sweden’s national critical infrastructure. (Photo: Business Wire)
“At Netnod, we’re committed to providing the market’s most advanced and reliable timing solutions. Our new Time Direct and Remote services, built on the latest timing standards and security protocols, underscore our leadership in this domain. The deployment of Adtran’s coreSync™ OSA 3300-HP is key for providing reliable, continuous timing for Sweden’s critical infrastructure. It enhances our NTP/PTP services and strengthens Sweden’s digital backbone for essential sectors, including 5G. It also provides the country with the benefits of highly precise synchronization resilient against GNSS vulnerabilities and enables us to deliver more valuable SLAs for our customers,” said Karin Ahl, CEO of Netnod. “This upgrade is about securing the digital backbone of our nation against GNSS cyber threats, generating economic growth and reinforcing our commitment to maintaining Sweden as a leader in digital innovation and infrastructure resilience.”
Netnod is integrating Oscilloquartz super ePRC technology across six key timing centers nationwide, including the coreSync™ OSA 3300-HP, for unprecedented reliability and accuracy. The upgrade is particularly crucial for timing service assurance within a secure environment. Given the increasing vulnerabilities of GNSS, the optically pumped cesium technology offers a highly stable and accurate alternative timing source. The coreSync™ OSA 3300-HP sets new standards with its higher frequency stability and lifespan that is twice as long as traditional magnetic clocks. Its robust design is complemented by a user-friendly LCD touchscreen and Ethernet connectivity, facilitating both local and remote configuration and management. This blend of advanced features enhances time synchronization across Sweden and prepares the nation’s infrastructure for future challenges.
“Netnod is a major hub for ICT and multimedia, serving as the gateway to the Nordics’ global digital arena. Leveraging our coreSync™ OSA 3300, it’s fortifying Sweden’s critical national infrastructure, ensuring seamless operations and growth for internet service providers, content delivery networks and businesses in one of Europe’s most dynamic digital markets,” commented Stuart Broome, GM of EMEA sales at Adtran. “With our technology, Netnod can utilize multiple timing sources, enabling a zero-trust environment for clients in next-gen telecoms, finance, utilities, broadcast and beyond. This will help equip enterprises and institutions across the region with top-tier internet speed, resilience and connectivity and solidify Netnod’s position as the digital cornerstone of the Nordics.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About Netnod
Netnod provides critical infrastructure support ranging from interconnection services and Internet Exchanges to time services, DNS services and root server operations. With a worldwide reputation for its services and the expertise of its staff, Netnod ensures a stable and secure Internet for the Nordics and beyond. Established in 1996 as a neutral and independent Internet infrastructure organisation, Netnod is fully owned by the non-profit foundation TU-stiftelsen (Stiftelsen för Telematikens utveckling). More information is available at: www.netnod.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311684053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
